Literature DB >> 15572428

Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk.

K K Miller1, B M K Biller, J G Lipman, G Bradwin, N Rifai, A Klibanski.   

Abstract

We hypothesized that endogenous GH would be reduced in healthy women with relative truncal adiposity despite lack of generalized obesity and that decreased GH would be associated with increased cardiovascular risk markers. Fifteen healthy female volunteers were divided into two groups, low truncal fat and high truncal fat, of comparable body mass index (BMI). Age and BMI (23.7 +/- 2.1 vs. 25.8 +/- 2.8 kg/m(2)) were similar in the two groups. Trunk fat was higher in the high-truncal-fat group, as designed. Twenty-four-hour mean GH, amplitude, and basal GH concentration were 41, 32, and 36% lower, respectively, in the high-truncal-fat group, but GH pulse frequency and IGF-I levels did not differ. In a stepwise regression model, trunk fat accounted for 38% of the variation of mean GH levels (P = 0.02), but neither total body fat nor BMI were significant determinants of mean GH in the model. There was a strong inverse association between mean 24-h GH and both truncal fat and cardiovascular risk markers, including high-sensitivity C-reactive protein. Our data suggest that visceral adiposity may be associated with reduced endogenous GH in healthy women, even in the absence of generalized obesity, and that decreased GH secretion may be associated with increased cardiovascular risk markers in this population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15572428     DOI: 10.1210/jc.2004-0894

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  37 in total

1.  Determinants of IGF1 and GH across the weight spectrum: from anorexia nervosa to obesity.

Authors:  D J Brick; A V Gerweck; E Meenaghan; E A Lawson; M Misra; P Fazeli; W Johnson; A Klibanski; K K Miller
Journal:  Eur J Endocrinol       Date:  2010-05-25       Impact factor: 6.664

Review 2.  The past 10 years-new hormones, new functions, new endocrine organs.

Authors:  Roger Bouillon; Daniel J Drucker; Ele Ferrannini; Steven Grinspoon; Clifford J Rosen; Paul Zimmet
Journal:  Nat Rev Endocrinol       Date:  2015-09-01       Impact factor: 43.330

Review 3.  Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?

Authors:  Laurent Peyrin-Biroulet; Mathias Chamaillard; Florent Gonzalez; Elodie Beclin; Cecilia Decourcelle; Laurent Antunes; Jérôme Gay; Christel Neut; Jean-Frédéric Colombel; Pierre Desreumaux
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

Review 4.  The metabolic effects of growth hormone in adipose tissue.

Authors:  Valéria Ernestânia Chaves; Fernando Mesquita Júnior; Gisele Lopes Bertolini
Journal:  Endocrine       Date:  2013-02-21       Impact factor: 3.633

5.  Relationship between sleep apnea, fat distribution, and insulin resistance in obese children.

Authors:  Craig A Canapari; Alison G Hoppin; T Bernard Kinane; Bijoy J Thomas; Martin Torriani; Eliot S Katz
Journal:  J Clin Sleep Med       Date:  2011-06-15       Impact factor: 4.062

6.  Effects of growth hormone withdrawal in obese premenopausal women.

Authors:  E Lin; M A Bredella; A V Gerweck; M Landa; D Schoenfeld; A L Utz; K K Miller
Journal:  Clin Endocrinol (Oxf)       Date:  2013-06       Impact factor: 3.478

Review 7.  The Impact of Fat and Obesity on Bone Microarchitecture and Strength in Children.

Authors:  Joshua N Farr; Paul Dimitri
Journal:  Calcif Tissue Int       Date:  2016-12-24       Impact factor: 4.333

8.  Peak growth hormone-releasing hormone-arginine-stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity.

Authors:  Miriam A Bredella; Martin Torriani; Bijoy J Thomas; Reza Hosseini Ghomi; Danielle J Brick; Anu V Gerweck; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2009-07-14       Impact factor: 5.958

9.  The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men.

Authors:  Hideo Makimura; Takara Stanley; David Mun; Sung Min You; Steven Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2008-09-02       Impact factor: 5.958

10.  Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women.

Authors:  Andrea L Utz; Ami Yamamoto; Linda Hemphill; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-04-29       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.